BATON ROUGE, La., July 06, 2022 (GLOBE NEWSWIRE) — Amedisys, Inc. (NASDAQ: AMED), a leading provider of quality home health, hospice, personal care and high-acuity care, will report results for the second quarter ended June 30, 2022, after the market closes on July 27, 2022. The Company will host an investor conference call to discuss these results at 11:00 a.m. ET on July 28, 2022.
To participate on the conference call, please call a few minutes before 11:00 a.m. ET to either (877) 524-8416 (toll-free) or (412) 902-1028 (toll). A replay of the call will be available through August 28, 2022, by dialing (877) 660-6853 (toll-free) or (201) 612-7415 (toll) and entering access ID 13731294.
A live webcast of the call will be accessible through the Company website on the Investor Relations section at https://investors.amedisys.com.
About Amedisys:
Amedisys, Inc. is a leading healthcare at home Company delivering personalized home health, hospice, personal care and high-acuity care services. Amedisys is focused on delivering the care that is best for our patients, whether that is home-based personal care; inpatient hospital, palliative, and skilled nursing facility (“SNF”) care in their homes; recovery and rehabilitation after an operation or injury; care focused on empowering them to manage a chronic disease; or hospice care at the end of life. More than 3,000 hospitals and 90,000 physicians nationwide have chosen Amedisys as a partner in post-acute care. Founded in 1982, headquartered in Baton Rouge, LA with an executive office in Nashville, TN, Amedisys is a publicly held company. With approximately 21,000 employees, in 549 care centers in 38 states and the District of Columbia, Amedisys is dedicated to delivering the highest quality of care to the doorsteps of more than 445,000 patients in need every year, performing more than 11.5 million visits annually. For more information about the Company, please visit: www.amedisys.com.
Contact: | |
Nick Muscato | Kendra Kimmons |
Amedisys, Inc. | Amedisys, Inc. |
Investor Relations | Media Relations |
615.928.5452 | 225.299.3720 |
nick.muscato@amedisys.com | Kendra.kimmons@amedisys.com |
LOS ANGELES, May 10, 2025 (GLOBE NEWSWIRE) -- Losing weight these days can feel more…
Late-breaking results from the open-label compensated MASH cirrhosis (F4c) arm of the Phase 3 MAESTRO-NAFLD-1…
Discover the 6 best fat burners for women in 2025. Top OTC & online weight…
Discover the best fat burners for men in 2025! Our expert guide ranks the top…
WOLFSON BRANDS (UK) LIMITED WOLFSON BRANDS (UK) LIMITED Glasgow, May 10, 2025 (GLOBE NEWSWIRE) --…
Two independent campaigns in NYC spotlight healthcare and legal reform amid public outcry over Luigi…